Submit Your Article CMED MEACR meeting
Home Print this page Email this page Users Online: 149
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2013  |  Volume : 2  |  Issue : 3  |  Page : 202-206

The safety and tolerability of FE 100 C-D chemotherapy in a non-trial population of node positive breast cancer compared to PACS-01 trial group; Salmaniya Medical Complex experience


1 Department of Oncology and Hematology, Salmaniya Medical Complex, Manama, Bahrain
2 Department of Endocrinology and Internal Medicine, Bahrain Defence Force Hospital, West Riffa, Bahrain
3 Department of Obstetrics and Gynaecology, Salmaniya Medical Complex, Manama, Bahrain

Correspondence Address:
Aysha Seddiq AL Zaman
PO Box 12, Department of Oncology and Hematology, Salmaniya Medical Complex, Manama
Bahrain
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2278-0513.119261

Rights and Permissions

Introduction: In our institution, adjuvant taxanes are currently offered to fit node-positive breast cancer patients who are either Her2 positive (any ER/PR) or triple negative (ER/PR/Her2 negative). The FE 100 C-D (FE100C × 3 → docetaxel 100 mg/m 2 × 3) regime, based on the PACS 01 trial1 is used. Materials and Methods: We retrospectively audited our experience with FE 100 C-D at Salmaniya Medical Complex. Over a 2-year-period, 100 patients commenced adjuvant FE100C-D chemotherapy. Data was matched with the FE 100 C-D arm of the PACS 01 trial. Results: Median age was 54 years. Twenty-six patients (26%) had ≥1 episode of febrile neutropenia (FN), including one fatal episode; 29% patients required treatment interruption ≥1 week; 30% patients had dose reductions; and 30% patients received < 90% dose intensity of docetaxel. Conclusion: The FN rate was substantially higher and docetaxel dose intensity substantially lower in our unselected sample of patients than in the trial population, this "real-life" data demonstrates the problems of applying clinical trial data to the more generalised patient population. Meanwhile, the routine use of prophylactic G-CSF support with this protocol is warranted.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1593    
    Printed39    
    Emailed1    
    PDF Downloaded71    
    Comments [Add]    
    Cited by others 1    

Recommend this journal